Annals of Thoracic and Cardiovascular Surgery
Online ISSN : 2186-1005
Print ISSN : 1341-1098
ISSN-L : 1341-1098
Original Articles
Is High Score of Preoperative Lactate Dehydrogenase to Albumin Ratio Predicting Poor Survivals in Esophageal Carcinoma Patients?
Fumiaki ShiratoriTakashi SuzukiSatoshi YajimaYoko OshimaTatsuki NanamiKimihiko FunahashiHideaki Shimada
Author information
JOURNAL OPEN ACCESS
Supplementary material

2023 Volume 29 Issue 5 Pages 215-222

Details
Abstract

Purpose: The lactate dehydrogenase-to-albumin ratio (LAR) has been reported as a potential prognostic biomarker in various cancers; however, only a few pieces of information have been reported on esophageal cancer. Therefore, this study aimed to evaluate the prognostic significance of preoperative LAR in patients with esophageal cancer.

Methods: This study included 236 patients (193 men and 43 women; mean age of 66 years [range, 41–83 years]) with esophageal cancer who underwent curative surgery between September 2008 and March 2020. A total of 107 patients underwent upfront surgery, and 129 patients received neoadjuvant treatment. Patients were assigned into two groups, high and low LAR, based on preoperative LAR using a cutoff value of 6.2. The clinicopathological and prognostic significance of preoperative LAR was evaluated in univariate and multivariate analyses.

Results: Patients with deep tumors and neoadjuvant treatment were significantly associated with high LAR (p <0.05). The high LAR group showed a significantly poorer prognosis than the low LAR group (p <0.01). The multivariate analysis for the overall survival showed that deep tumors, lymph node metastasis, and high LAR were independent poor prognostic factors (p <0.05).

Conclusion: High LAR was a useful poor prognostic biomarker in patients with esophageal cancer.

Content from these authors
© 2023 The Editorial Committee of Annals of Thoracic and Cardiovascular Surgery

This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.
https://creativecommons.org/licenses/by-nc-nd/4.0/
Next article
feedback
Top